Trial Profile

A clinical trial of Ropivacaine Hydrochloride Liposome Suspension Injection

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 May 2021 According to a Luye Pharma Group media release, Ropivacaine Hydrochloride Liposome Suspension Injection (LY09606), has been granted approval for clinical trials by the Centre for Drug Evaluation of China National Medical Products Administration.
12 Mar 2021 New trial record
08 Mar 2021 According to a Luye Pharma Group media release, clinical trial application for the company self-developed innovative formulation, Ropivacaine Hydrochloride Liposome Suspension Injection (LY09606), has received formal acceptance from the Center for Drug Evaluation of the National Medical Products Administration in China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com